J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (NASDAQ: REGN) on August 17. The company’s shares closed yesterday at $374.80.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.6% and a 41.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Regeneron is a Hold with an average price target of $385.56, a 2.9% upside from current levels. In a report issued on August 3, Robert W. Baird also downgraded the stock to Hold with a $405 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $505.49 and a one-year low of $281.89. Currently, Regeneron has an average volume of 780.8K.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
